Addition of pulse corticosteroids to oral prednisone in moderately active ulcerative colitis: a randomized, multicentre, open-label study by GETECCU
Por:
Llao, J, Mañosa, M, Martín-Arranz, E, Zabana, Y, Navarro-Llavat, M, Téller, M, Garcia-Planella, E, Busquets, D, Monfort, D, Pineda, JR, Gutiérrez, A, Villoria, A, Menchén, L, Bastida, G, García-Alonso, FJ, Rivero, M, Chaparro, M, de Francisco, R, Merino, O, Rodríguez-Lago, I, Acosta, MBD, Rodríguez-Fortúnez, P, Rodríguez-Jiménez, C, Calafat, M and Domènech, E
Publicada:
1 nov 2025
Resumen:
Background Oral corticosteroids remain the treatment of choice for moderately active ulcerative colitis (UC), achieving clinical remission in 30%-60% of patients.Objective To compare the rates of steroid-free clinical-endoscopic remission at weeks 8 and 54 in patients treated with 3 methyl-prednisolone pulses before oral corticosteroids in moderately active UC versus those only receiving oral corticosteroids.Design Prospective, open, multicentre, randomized, controlled trial. Patients with left/extensive, moderately active UC, naive to immunosuppressants and biological agents, were randomized to receive conventional treatment (CT) with oral prednisone 60 mg/day or the same regimen preceded by an additional daily pulse (AP) of 500 mg of methyl-prednisolone for 3 days. All patients who responded started oral mesalazine and were followed up until month 12 or clinical relapse.Results Seventy-five patients were randomized: 39 were allocated to the CT arm and 36 to the AP arm. Overall, 21 patients achieved clinical-endoscopic remission (28%; 95% confidence interval [CI]: 23%-33%) at both weeks 8 and 54 without needing rescue treatments, being not significantly different between both study groups (23% [95%CI: 14%-32%] CT vs. 33% [95%CI: 21%-45%] AP; P = 0.323). Patients in the AP group had higher rates of clinical response at day 3 and remission at day 7. No significant differences in adverse events were observed. Due to early termination, the study was underpowered, and findings should be interpreted as exploratory.Conclusions The addition of 3 pulses of high-dose corticosteroids to a conventional regimen of oral prednisone does not improve medium and long-term clinical outcomes in moderately active UC.Trial registration codes EudraCT number 2016-001170-15; ClinicalTrials.gov identifier NCT02921555.
Filiaciones:
Llao, J:
Hosp Badalona Germans Trias & Pujol, Gastroenterol & Hepatol Dept, Ctra Canyet S-N, Badalona 08916, Catalonia, Spain
Xarxa Assistencial Althaia, Gastoenterol Dept, Manresa, Spain
:
Hosp Badalona Germans Trias & Pujol, Gastroenterol & Hepatol Dept, Ctra Canyet S-N, Badalona 08916, Catalonia, Spain
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Martín-Arranz, E:
Hosp Univ La Paz Idipaz, H Univ La Paz, Gastoenterol Dept, Inst Invest Sanitaria, Madrid, Spain
Zabana, Y:
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
HU Mutua Terrassa, Gastoenterol Dept, Terrassa, Spain
Navarro-Llavat, M:
H Moises Broggi, Gastoenterol Dept, Sant Joan Despi, Spain
Téller, M:
Xarxa Assistencial Althaia, Gastoenterol Dept, Manresa, Spain
Garcia-Planella, E:
H Santa Creu & St Pau, Gastoenterol Dept, Barcelona, Spain
Busquets, D:
H Trueta, Gastoenterol Dept, Girona, Spain
Monfort, D:
Consorci Sanit Terrassa, Gastoenterol Dept, Terrassa, Spain
Pineda, JR:
H Alvaro Cunqueiro, Gastoenterol Dept, Vigo, Spain
Gutiérrez, A:
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
HG Univ Dr Balmis & ISABIAL, Gastoenterol Dept, Alicante, Spain
Villoria, A:
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Consorci Sanit Parc Tauli, Gastoenterol Dept, Sabadell, Spain
Menchén, L:
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Univ Complutense, H Gen Univ, Gastoenterol Dept, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain
Bastida, G:
H Univ & Politecn La Fe, Gastoenterol Dept, Valencia, Spain
García-Alonso, FJ:
H Univ Rio Hortega, Gastoenterol Dept, Valladolid, Spain
Rivero, M:
Hosp Univ Marques Valdecilla, Grp Invest Clin & Traslac Enfermedades Digest, Inst Invest Valdecilla IDIVAL, Santander, Spain
Chaparro, M:
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Univ Autonoma Madrid, H Univ La Princesa, Gastoenterol Dept, Inst Invest Sanitaria Princesa, Madrid, Spain
de Francisco, R:
H Univ Cent Asturias, Gastoenterol Dept, Inst Invest Sanitaria Principado Asturias ISPA, Oviedo, Spain
Merino, O:
H Cruces, Gastoenterol Dept, Bilbao, Spain
Rodríguez-Lago, I:
Hosp Univ Galdakao, Gastoenterol Dept, Inst Invest Sanitaria Biobizkaia, Galdakao, Spain
Acosta, MBD:
Complejo Hosp Santiago, Gastoenterol Dept, Santiago De Compostela, Spain
Rodríguez-Fortúnez, P:
UICEC H Univ Canarias, San Cristobal De La Lagun, Spain
Rodríguez-Jiménez, C:
UICEC H Univ Canarias, San Cristobal De La Lagun, Spain
:
Hosp Badalona Germans Trias & Pujol, Gastroenterol & Hepatol Dept, Ctra Canyet S-N, Badalona 08916, Catalonia, Spain
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
:
Hosp Badalona Germans Trias & Pujol, Gastroenterol & Hepatol Dept, Ctra Canyet S-N, Badalona 08916, Catalonia, Spain
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Univ Autonoma Barcelona, Barcelona, Spain
|